Home   Categories   Grid

Subscribe Now

Avacta completes move away from Whittlesford to White City

Avacta completes move away from Whittlesford to White City

Avacta completes move away from Whittlesford to White City

18 May 2022

The company has brought its R&D teams together in London.


AstraZeneca revenues rise 60% to $11bn in first quarter as it unveils plans for new Alexion headquarters

AstraZeneca revenues rise 60% to $11bn in first quarter as it unveils plans for new Alexion headquarters

AstraZeneca revenues rise 60% to $11bn in first quarter as it unveils plans for new Alexion headquarters

04 May 2022

Meanwhile, it expects sales of its Covid-19 vaccine to decline in 2022.


Dengue threat to be tackled using AI-powered drug discovery as BenevolentAI teams up with DNDi

Dengue threat to be tackled using AI-powered drug discovery as BenevolentAI teams up with DNDi

Dengue threat to be tackled using AI-powered drug discovery as BenevolentAI teams up with DNDi

28 April 2022

There are an estimated 390 million infections each year.


Spanish medical imaging specialist Quibim heads to Cambridge after support

Spanish medical imaging specialist Quibim heads to Cambridge after support

Spanish medical imaging specialist Quibim heads to Cambridge after support

22 April 2022

Growth Works and Eastern AHSN helped the company as it scales.


Mursla’s nanochip technology for exosome detection poised to transform disease diagnosis

Mursla’s nanochip technology for exosome detection poised to transform disease diagnosis

Mursla’s nanochip technology for exosome detection poised to transform disease diagnosis

21 April 2022

The Cambridge Science Park company is also working with Roche Diagnostics on a liver cancer pilot study.


Avacta achieves AffyXell joint venture milestone, triggering increased equity stake

Avacta achieves AffyXell joint venture milestone, triggering increased equity stake

Avacta achieves AffyXell joint venture milestone, triggering increased equity stake

20 April 2022

It has developed and characterised Affimer proteins against the first target for AffyXell.


How Adrestia Therapeutics is pioneering synthetic rescue

How Adrestia Therapeutics is pioneering synthetic rescue

How Adrestia Therapeutics is pioneering synthetic rescue

14 April 2022

An interview with Prof Steve Jackson and CEO Robert Johnson


Axol Bioscience raises further £3.2m to extend iPSC products for drug discovery market

Axol Bioscience raises further £3.2m to extend iPSC products for drug discovery market

Axol Bioscience raises further £3.2m to extend iPSC products for drug discovery market

13 April 2022

It extends the total raised to £7m.


BiologIC’s biocomputer invention to be used by Oxford Biomedica to develop viral vectors for cancer therapies

BiologIC’s biocomputer invention to be used by Oxford Biomedica to develop viral vectors for cancer therapies

BiologIC’s biocomputer invention to be used by Oxford Biomedica to develop viral vectors for cancer therapies

31 March 2022

The Cambridge biotech wants to ‘drive a revolution in biology’.


Sosei Heptares confirms new leadership focused on driving growth from its Granta Park R&D centre

Sosei Heptares confirms new leadership focused on driving growth from its Granta Park R&D centre

Sosei Heptares confirms new leadership focused on driving growth from its Granta Park R&D centre

31 March 2022

New CEO and new head of UK R&D confirmed.


Drug identified by BenevolentAI shown to reduce deaths in patients hospitalised by Covid-19

Drug identified by BenevolentAI shown to reduce deaths in patients hospitalised by Covid-19

Drug identified by BenevolentAI shown to reduce deaths in patients hospitalised by Covid-19

10 March 2022

Results have been published from the University of Oxford RECOVERY trial.


Adrestia Therapeutics appoints first full-time CEO as it builds synthetic rescue therapy platform

Adrestia Therapeutics appoints first full-time CEO as it builds synthetic rescue therapy platform

Adrestia Therapeutics appoints first full-time CEO as it builds synthetic rescue therapy platform

10 March 2022

Robert Johnson previously co-founded Boston-based gene therapy company Affinia Therapeutics.


University of Cambridge spin-out DIOSynVax to receive $42m to develop universal coronavirus vaccine

University of Cambridge spin-out DIOSynVax to receive $42m to develop universal coronavirus vaccine

University of Cambridge spin-out DIOSynVax to receive $42m to develop universal coronavirus vaccine

08 March 2022

Prime Minister Boris Johnson announce the funding at the Global Pandemic Preparedness Summit.


Stem cell discovery at Babraham Institute creates opportunity to study our genomic wake-up call

Stem cell discovery at Babraham Institute creates opportunity to study our genomic wake-up call

Stem cell discovery at Babraham Institute creates opportunity to study our genomic wake-up call

04 March 2022

The discovery could help us explore the earliest events in our development.


Private testing lab network must be maintained as Covid-19 tests reduce, says Cambridge Clinical Laboratories CEO

Private testing lab network must be maintained as Covid-19 tests reduce, says Cambridge Clinical Laboratories CEO

Private testing lab network must be maintained as Covid-19 tests reduce, says Cambridge Clinical Laboratories CEO

03 March 2022

Dr Tony Cooke has become chair of the scientific advisory board for The Laboratory and Testing Industry Organisation.


Genomics company Broken String Biosciences sets up new home at Chesterford Research Park

Genomics company Broken String Biosciences sets up new home at Chesterford Research Park

Genomics company Broken String Biosciences sets up new home at Chesterford Research Park

03 March 2022

It follows a seed funding round of about £3m.


Health secretary Sajid Javid visits Cambridge Biomedical Campus on ‘Road to Recovery’ tour

Health secretary Sajid Javid visits Cambridge Biomedical Campus on ‘Road to Recovery’ tour

Health secretary Sajid Javid visits Cambridge Biomedical Campus on ‘Road to Recovery’ tour

19 February 2022

Mr Javid visited the campus as part of a tour of the East of England.


Addenbrooke’s oncologist welcomes NICE decision to approve GSK drug for advanced endometrial cancer

Addenbrooke’s oncologist welcomes NICE decision to approve GSK drug for advanced endometrial cancer

Addenbrooke’s oncologist welcomes NICE decision to approve GSK drug for advanced endometrial cancer

11 February 2022

It is the first new treatment in this indication for years.


AstraZeneca CEO: ‘It’s hard to have regrets when Covid-19 vaccine has saved one million lives’

AstraZeneca CEO: ‘It’s hard to have regrets when Covid-19 vaccine has saved one million lives’

AstraZeneca CEO: ‘It’s hard to have regrets when Covid-19 vaccine has saved one million lives’

10 February 2022

Pascal Soriot was speaking as the company revealed stellar results from a ‘landmark’ year.


Biofidelity raises further $23m as it moves towards launch of ASPYRE-Lung diagnostic product

Biofidelity raises further $23m as it moves towards launch of ASPYRE-Lung diagnostic product

Biofidelity raises further $23m as it moves towards launch of ASPYRE-Lung diagnostic product

10 February 2022

It will make biomarker testing faster, more affordable and more accessible.


This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More